Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

Model scores of the 29,894 trials active now.

Model score 28% for any early termination, 13% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-05-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerstageradiationpatients mustfunction
  Phrases that lowered it: maledrugsdruginteractionadministration of
• Sponsor's past termination rate: 28.6% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Keywords listed: 7 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 171 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 448 (lowers risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Drug's FAERS reports with a death: 19.9% (lowers risk) · Drug's FDA history
• Primary purpose: prevention (lowers risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 3 (lowers risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients NCT00817531 · started 2008 · scored riskier than 99% of active trials terminated
• Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer NCT00924352 · started 2009 · scored riskier than 99% of active trials completed
• Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194 NCT00820170 · started 2009 · scored riskier than 66% of active trials completed
• Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients NCT01306942 · started 2011 · scored riskier than 99% of active trials completed
• Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer NCT00903006 · started 2009 · scored riskier than 94% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.